Among them, Endocan [8,9], placental growth factor (PLGF) [10,11], Galectin-3 [12,13], Fetuin-A [14,15], and Cathepsin D [16,17] have been demonstrated to act as important CV risk predictors in the CKD patients; therefore, they were selected to be analyzed in our study. This evidence concerns the gene PGF and chronic kidney disease.